Follow-up from REVEAL is planned in 4 years, which means that barring any new safety signals, anacetrapib would be submitted for approval in about 2015, Dr. Cannon said in an interview.
Results of DEFINE were published online simultaneously with Dr. Cannon’s presentation (N. Engl. J. Med. 2010 [doi:10.1056/NEJMoa1009744]).
DEFINE was supported by Merck Research Laboratories. Dr. Cannon and his co-authors report financial relationships with several pharmaceutical firms including Merck. Dr. Cannon also serves as an advisor and holds equity in Automedics Medical Systems.